'%20id='ico-down'%20stroke='%23000000'%20stroke-width='1.5'%3e%3cg%20transform='translate(1092.250000,%20254.750000)'%3e%3cpolyline%20id='Path-2-Copy-4'%20transform='translate(5.500000,%202.750000)%20scale(1,%20-1)%20rotate(-180.000000)%20translate(-5.500000,%20-2.750000)%20'%20points='0%200%205.5%205.5%2011%200'%3e%3c/polyline%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
21 October 2004
BERLIN – German pharmaceuticals concern Schering AG reported Thursday that its profit through September reached EUR 595 million, up 10 percent on the same nine-month period last year.
Company chairman Hubertus Erlen said that revenues had risen 3 percent to just over EUR 3.64 billion, keeping Germany’s third-largest pharmaceuticals company on course to meet full-year targets for 2004.
He said that Schering now expected its 2004 earnings per share to reach EUR 2.35, up from the previously-projected EUR 2.26, thanks to lower tax charges.
In another development, Erlen said Schering will in the future report the salaries paid to executive board members individually in a further step towards transparency. Till now, the company has only reported the board chairman’s remuneration.
DPA
Subject: German news